Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer
The improvement in response did not translate to a survival benefit.
New Symptoms ID’d That May Indicate Pancreatic Cancer
Researchers identified 23 symptoms associated with pancreatic ductal adenocarcinoma.
2000 to 2018 Saw Increase in Incidence of Pancreatic Cancer
From 2000 to 2018, there were 283,817 cases of pancreatic cancer reported.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Eligibility Criteria for Pancreatic Cancer Trials Exclude More Black Patients Than White Patients
Standard eligibility criteria perpetuate racial disparities and are often not medically justifiable, according to researchers.
Napabucasin Provides No Added Benefit in Metastatic Pancreatic Cancer
The phase 3 CanStem111P study was terminated early due to futility.
Sex Inequalities Persist in Cancer Clinical Trials
Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.
Rucaparib Maintenance Deemed Safe, Effective for Advanced Pancreatic Cancer
Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.
Minority Patients Remain Underrepresented in Clinical Trials of Pancreatic Cancer
Non-White and non-Hispanic patients were underrepresented throughout the period studied.
SBRT Plus Pembrolizumab and Trametinib Confers Survival Benefits in Pancreatic Cancer
Stereotactic body radiotherapy plus pembrolizumab and trametinib improved overall and progression-free survival.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Study Supports Maintenance Over Sequential Treatment Strategy in Metastatic Pancreatic Cancer
A sequential treatment strategy was less effective than a maintenance strategy.
Adding Nab-Paclitaxel to Gemcitabine May Improve Overall Survival in Resected Pancreatic Cancer
Nab-paclitaxel was associated with an improvement in long-term overall survival.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Hypofractionated A-RT After Chemotherapy Resulted in Locoregional Control in Pancreatic Cancer
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.
Contrast-Enhanced vs Conventional Endoscopic Ultrasound for Diagnosis of Pancreatic Lesions
A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
Loading... 
Loading...